ACAT1/SOAT1在糖尿病视网膜病变中的新作用
研究在Ins2Akita糖尿病小鼠中给予ACAT1/SOAT1抑制剂K604(10 mg/kg腹腔注射),评估视网膜胆固醇酯、氧化应激、炎症及血管和视网膜功能。结果显示抑制ACAT1/SOAT1可减轻早期和晚期DR的视网膜损伤,且不依赖血糖或体重变化。
要点
- ACAT1/SOAT1介导的胆固醇酯化在DR视网膜中升高。
- K604抑制ACAT1/SOAT1可减少氧化应激、炎症和血管渗漏。
- 该保护作用独立于系统血糖和体重变化。
核心结论
- 抑制ACAT1/SOAT1可正常化其表达和胆固醇酯形成,预防氧化应激和炎症,限制早期和晚期DR的血管及视网膜功能障碍。
- ACAT1/SOAT1是治疗糖尿病视网膜病变的潜在靶点。
研究设计与样本
- Ins2Akita小鼠从10至12周或8至10个月接受ACAT1/SOAT1抑制剂K604(10 mg/kg,腹腔注射)治疗。
- 通过ELISA、qPCR、Western blot、白细胞停滞和通透性实验、视网膜电图和OptoMotry评估血浆和视网膜胆固醇酯、氧化应激、炎症、血管病理和视网膜功能。
- 在DR供体视网膜切片和玻璃体样本中检测ACAT1/SOAT1表达和胆固醇酯水平。
主要发现
- 12周龄Ins2Akita小鼠视网膜胆固醇酯和超氧化物增加,ACAT1/SOAT1、LDLR、TREM1、MCSF和VEGF表达升高,伴白细胞停滞、高通透性、无细胞毛细血管、视网膜神经节细胞丢失及视网膜电图和视觉 acuity功能受损,K604治疗抑制这些变化。
- 10月龄Ins2Akita小鼠视网膜同样显示ACAT1/SOAT1、LDLR、TREM1、MCSF、胆固醇酯、超氧化物、高通透性和视网膜电图及acuity反应受损增加,K604可抑制这些改变。
- 这些保护效应独立于系统葡萄糖或体重变化。
关键数值与推荐
- K604剂量为10 mg/kg,腹腔注射,治疗时间窗为10至12周或8至10个月龄。
临床怎么用
- ACAT1/SOAT1抑制可能成为糖尿病视网膜病变的治疗策略,但需进一步临床验证。
局限性
- 研究仅基于Ins2Akita小鼠模型和离体人供体样本,尚未在临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hypercholesterolemia has been linked to inflammation and vascular dysfunction in diabetic retinopathy (DR). Excessive cholesterol ester (CE) production in macrophages can induce increases in inflammatory and angiogenic cytokines. AcylCoA:cholesterol acyltransferase 1/Sterol O-acyltransferase 1 (ACAT1/SOAT1) is responsible for cholesterol esterification. Here we determine its role in diabetic retinopathy (DR). We hypothesized that DR-induced increases in ACAT1/SOAT1-mediated CE formation triggers retinal inflammation and injury. METHODS: Ins2Akita mice were treated with the ACAT1/SOAT1 inhibitor K604 (10 mg/kg, intraperitoneally) from 10 to 12 weeks or eight to 10 months. Plasma and retinal CE, oxidative stress, inflammation, vascular pathology, and retinal function were assessed by ELISA, qPCR, Western blot, leukostasis and permeability assays, electroretinography (ERG), and OptoMotry. ACAT1/SOAT1 expression and CE levels were assayed in retinal sections and vitreous samples from DR donors. RESULTS: Retinas from 12-week-old Ins2Akita mice exhibited increases in CE and superoxide, and expression of ACAT1/SOAT1, LDLR, TREM1, MCSF, and VEGF along with leukostasis, hyperpermeability, acellular capillaries, retinal ganglion cell loss, and impaired ERG and visual acuity function. K604 treatment inhibited these changes. Retinas from 10-month-old Ins2Akita mice also showed increased ACAT1/SOAT1, LDLR, TREM1, MCSF, CE, superoxide, hyperpermeability, and impaired ERG and acuity responses that were inhibited by K604. These protective effects were independent of changes in systemic glucose or body weight. CONCLUSIONS: ACAT1/SOAT1 inhibition normalizes ACAT1/SOAT1 expression and CE formation, prevents oxidative stress and inflammation, and limits vascular and retinal dysfunction in both early- and late-stage DR. These findings identify ACAT1/SOAT1 as a promising target for treatment of DR.
引用
- Zaidi SAH, Lemtalsi T, Xu Z, et al. Novel Role of AcylCoA: Cholesterol Acyltransferase 1/Sterol O-Acyltransferase 1 (ACAT1/SOAT1) in Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2026. PMID: 42496660. doi:10.1167/iovs.67.8.52
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。